Editor's Corner


Pfizer's well-considered decision to halt all DTC ads for at least six months after product approval -- along with a commitment to do a better job in providing consumers better information about a drug -- helps provide a useful model for other drug companies to follow as they determine how to respond to PhRMA's voluntary guidelines on the issue. But Pfizer's position also helps underscore why voluntary guidelines aren't going to work for the industry. If Pfizer chooses a six-month delay, GlaxoSmithKline opts for a year, and others won't agree to any required delay at all, what we end up with is a hodgepodge of conflicting standards and rationales. It would be infinitely better to adopt reasonable, rational guidelines that the industry could live with and consumers would benefit by. PhRMA's role here is to prevent the industry from looking like the gang that couldn't shoot straight -- not encourage it to act in such an awkward, conflicting fashion. Once you recognize something needs to be done, it's important to clarify how it's done properly. - John Carroll

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.